NVAX Novavax Inc
Company Analysis
Latest News
🔴 Novavax is trading 10% down as plague-scare enthusiasm fades
Novavax is trading at $11.54, down -10.02%, as investors reassess enthusiasm around the Russian plague scare after the WHO said the risk to the general...
🔴 Novavax is trading 7.18% down with no identified company-specific catalyst
Novavax is trading 7.18% down at $11.90 on October 16, based on the live price provided; no reliable report identifies a company-specific catalyst. - A...
🟢 Novavax is trading 12.8% up; catalyst remains unclear
Novavax is trading at $12.42 with a +12.80% move; the cause of the October 9 rise remains unclear. - Available coverage surfaced no clear company-specific...
🟢 Novavax is trading 6% up; no clear catalyst identified
Novavax is trading at $11.65, up 5.86%, with no clear catalyst identified for the October 9 gain. - No fresh company-specific announcement surfaced in the...
🔴 Novavax is trading 11% down today as October 5's speculative vaccine rally unwinds
Novavax is trading at $11.22, down -10.63%, as speculative gains from its October 5 surge unwind. - Novavax’s 20.08% October 5 surge followed speculation...
🔴 Novavax is trading 7% down today with no clear new catalyst reported
Novavax is trading at $11.69, down 6.92%, with no clear new company-specific catalyst reported for the October 6 decline. - It is giving back part of its...
🟢 Novavax is trading 5% up as vaccine stocks rallied on Russian plague concerns
Novavax is trading at $13.22, up 5.29%, amid a vaccine-sector rally linked to reports of an unexplained death at a Russian plague research institute. -...
Novavax's Combo Vaccine Clears a Key Hurdle — But Can a $10 Stock Compete in a $10 Billion Race?
Shares of Novavax shifted higher as the biotech announced positive Phase 3 results for its combination flu-COVID vaccine, a single shot designed to replace two...
Novavax Shares Soar on Positive Phase 3 Results for Combination Flu-COVID Vaccine
Novavax announced positive results from its pivotal Phase 3 trial of a combination influenza and COVID-19 vaccine. The trial met all primary endpoints, with...
🟢 Novavax is trading 5.4% up today — no clear company-specific catalyst identified
Novavax is trading at $10.97, up +5.38%, with no clear company-specific announcement identified for the September 22, 2026 move. - Latest listed company...
🟢 Novavax is trading 5% up today as broad risk appetite lifts U.S. equities
Novavax is trading 5.09% up at $10.62 as broad risk appetite lifts U.S. equities on September 21, 2026. - The S&P 500, Nasdaq Composite, and Dow Jones are all...
🟢 Novavax is trading 10% up today as biotech shares rally
Novavax is trading 10.32% up now at $10.31 as biotechnology shares rally alongside broader risk appetite. - The XBI biotech ETF is up 2.55%, supported by...
🟢 Novavax is trading 5% up today as biotech sector gains on M&A optimism
Novavax is trading 5.24% up at $9.88, primarily as biotechnology stocks strengthen alongside broader sector gains. - The XBI sector ETF is up 2.55% during...
🟢 Novavax is trading 5.43% up today after strategy update highlights licensing and Matrix-M applications
Novavax is trading 5.43% up now at $9.80 after management’s September 10, 2026 strategy update emphasized licensing partnerships, Matrix-M applications, and a...
Novavax Shifts to Licensing Model, Targeting Profitability by 2028
At the Citi BioPharma Back to School Conference, Novavax detailed a strategic shift toward a licensing-led business model. The company is leveraging its...
🔴 Novavax is trading 6.8% down today after opening-market selling
Novavax is trading 6.8% down at $9.18 after opening-market selling on September 10, 2026. - The Nasdaq Composite is down 0.80% as investors reassess...
🟢 Novavax is trading 5.3% up today after XFG-adapted Nuvaxovid approvals in U.S., EU and Japan
Novavax is trading 5.3% up at $9.87 after partners received approvals for XFG-adapted Nuvaxovid in the United States, European Union, and Japan for the...
🟢 Novavax is trading 6.26% up today after Nuvaxovid approvals in U.S., EU and Japan
Novavax is trading at $9.84, up +6.26%, after partners received approvals for its XFG-adapted Nuvaxovid vaccine in the United States, European Union, and Japan...
Novavax Wins FDA Approval for COVID Vaccine, Offering mRNA Alternative
The FDA approved Novavax’s updated protein-based COVID-19 vaccine for the 2026-2027 immunization season. The shot provides a non-mRNA alternative to vaccines...
🟢 Novavax rises 5.5% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...